Detalles de la búsqueda
1.
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study.
Hepatology
; 77(3): 760-773, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36152015
2.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lancet Oncol
; 22(7): 946-958, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34143969
3.
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Breast Cancer Res Treat
; 184(1): 53-62, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32803633
4.
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Lancet Oncol
; 20(11): 1587-1601, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31575503
5.
Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.
Int J Cancer
; 142(11): 2355-2362, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29313979
6.
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.
BMC Cancer
; 17(1): 137, 2017 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28202004
7.
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.
Breast Cancer Res Treat
; 155(2): 295-302, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26749361
8.
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Invest New Drugs
; 34(5): 625-35, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27350064
9.
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Oncology
; 91(5): 251-260, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27598338
10.
R.A.P.I.D. (Root Aggregated Prioritized Information Display): A single screen display for efficient digital triaging of medical reports.
J Biomed Inform
; 61: 214-23, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27064060
11.
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Invest New Drugs
; 33(1): 148-58, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25260842
12.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Lancet Oncol
; 15(1): 48-58, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24332241
13.
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Cancer Immunol Immunother
; 63(8): 787-96, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24770667
14.
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Cancer
; 119(14): 2555-63, 2013 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23605883
15.
Hemodynamic Gain Index and Exercise Capacity in Heart Failure With Preserved Ejection Fraction.
Am J Cardiol
; 190: 17-24, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36543076
16.
Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers.
JCO Precis Oncol
; 7: e2200679, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37467458
17.
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
J Thorac Oncol
; 18(7): 907-921, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36842467
18.
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Invest New Drugs
; 30(3): 1232-40, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21922186
19.
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
Invest New Drugs
; 30(4): 1591-6, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21863237
20.
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.
Clin Cancer Res
; 28(4): 629-636, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887261